(Q44235811)

1 December 2017

Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? (English)

1 reference

1 December 2017

Pseudomonas aeruginosa

1 reference

3

Joseph L Kuti

1 reference

1 December 2017

4

David P Nicolau

1 reference

1 December 2017

Aryun Kim

1

1 reference

PubMed ID

17963458

1 December 2017

Christina A Sutherland

series ordinal

2

1 reference

PubMed ID

17963458

1 December 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

1 December 2017

1 reference

1 December 2017

27

1 reference

1 December 2017

11

1 reference

1 December 2017

1490-1497

1 reference

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

1 December 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.11.1490

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.11.1490

1 reference

1 December 2017

1 reference

PubMed ID

17963458